Barclays
IMCR icon

Barclays’s Immunocore IMCR Stock Holding History

Barclays’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-43,800
Closed -$2.85M – 5071
2024
Q1 		$2.85M Buy
43,800
+25,000
+133% +$1.72M ﹤0.01% 2277
2023
Q4 		$1.28M Buy
+18,800
New +$977K ﹤0.01% 3252

Other funds holding IMCR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Barclays's IMCR Position: Q1 2026 in Review

Barclays reduced its Immunocore (IMCR) stake by 70% in Q1 2026, selling an estimated $2.34M and leaving 30,909 shares worth $932K. The position accounts for ﹤0.01% of the portfolio, ranked #2802.

Barclays first reported a position in IMCR in Q1 2022 and has held it in 17 quarters since. The position peaked at $11.8M in Q2 2023. 142 funds tracked by Wall St. Rank hold IMCR as of Q1 2026.

  • Barclays held 30,909 shares of Immunocore worth $932K as of Q1 2026.
  • Barclays sold 72,344 Immunocore shares in Q1 2026, an estimated $2.34M.
  • Immunocore made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2802 holding.
  • Barclays first reported a position in Immunocore in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Immunocore position peaked at $11.8M in Q2 2023.
  • 142 funds tracked by Wall St. Rank held Immunocore as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.